arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Vivos Therapeutics, Inc.

VVOS
$0.15 ▼ -0.01 (-4.66%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
28 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Vivos Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $2.7M
Dividend Yield
Revenue Growth 34.9%
Op. Margin -93.6%
ROIC 117.9%
FCF / Share $-0.20
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.15
info Valuation on last close. End-of-day price, Sep 23, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.15M
↑ +34.9%
Net Income Profit after all expenses
$-5.48M
↓ -41.8%
Operating Margin Operating profit as % of sales
-93.6%
↑ +27.2% 2th
FCF / Share Free cash flow per share
$-0.20
↑ +51.1%
Long-Term Debt Long-term obligations
$582.00K
↓ -5.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Financial Health
63
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 28 quarters